DOI: 10.36347/sjams.2020.v08i02.047

Pages: 623-629

Pulmonary embolism (PE) is a common, severe, multi-factorial disease that increases with age, and is one of the leading causes of death, largely due to delayed diagnosis and treatment. It is said to be severe or at high risk if it is associated with hemodynamic instability (arterial hypotension or cardiogenic shock). Thrombolysis is the recommended treatment for severe pulmonary embolism, the particularity of our study is the off-label use of Tenecteplase, a thrombolytic drug widely used in acute coronary syndrome, with results showing efficacy and tolerance compared to other molecules, through a retrospective study conducted in Cardiology B departement, between January 2015 and January 2016, involving 3 patients admitted for management of severe pulmonary embolism.